A redox-silent analogue of tocotrienol inhibits cobalt(II) chloride-induced VEGF expression via yes signaling in mesothelioma cells

Biological and Pharmaceutical Bulletin

Volumn 37, Issue 5, 2014, Pages 865-870

  Sato, Ayami ^a   Virgona, Nantiga ^a   Ando, Akira ^b   Ota, Masako ^a   Yano, Tomohiro ^a  

^a TOYO UNIVERSITY   (Japan)

^b SETSUNAN UNIVERSITY   (Japan)

Author keywords

Hypoxia Inducible Factor (HIF); Mesothelioma; Redox silent analogue; Tocotrienol; Vascular Endothelial Growth Factor (VEGF); Yes

Indexed keywords

6 O CARBOXYPROPYL ALPHA TOCOTRIENOL; ANTINEOPLASTIC AGENT; COBALT CHLORIDE; HYPOXIA INDUCIBLE FACTOR 2ALPHA; PROTEIN KINASE YES; UNCLASSIFIED DRUG; VASCULOTROPIN; 6-O-CARBOXYPROPYL-ALPHA-TOCOTRIENOL; ALPHA TOCOTRIENOL; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; COBALT; ENDOTHELIAL PAS DOMAIN-CONTAINING PROTEIN 1; VASCULOTROPIN A; YES1 PROTEIN, HUMAN;

ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; GENE EXPRESSION; HUMAN; HUMAN CELL; HYPOXIA; MESOTHELIOMA; PARACRINE SIGNALING; PROTEIN SECRETION; SIGNAL TRANSDUCTION; UPREGULATION; VEGF GENE; ANOXIA; BIOSYNTHESIS; CELL SURVIVAL; CHEMICALLY INDUCED; DRUG EFFECTS; METABOLISM; OXIDATION REDUCTION REACTION; PATHOLOGY; SECRETION (PROCESS); TUMOR CELL LINE;

ANOXIA; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CELL LINE, TUMOR; CELL SURVIVAL; COBALT; GENE EXPRESSION; HUMANS; MESOTHELIOMA; OXIDATION-REDUCTION; PROTO-ONCOGENE PROTEINS C-YES; SIGNAL TRANSDUCTION; TOCOTRIENOLS; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84899849210     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b13-00846     Document Type: Article

References (25)

1. Carbone M, Kratzke RA, Testa JR. The pathogenesis of mesothelioma. Semin. Oncol., 29, 2-17 (2002).
2. Palumbo C, Bei R, Procopio A, Modesti A. Molecular targets and targeted therapies for malignant mesothelioma. Curr. Med. Chem., 15, 855-867 (2008).
3. Zucali PA, Ceresoli GL, De Vincenzo F, Simonelli M, Lorenzi E, Gianoncelli L, Santoro A. Advances in the biology of malignant pleural mesothelioma. Cancer Treat. Rev., 37, 543-558 (2011).
4. Strizzi L, Catalano A, Vianale G, Orecchia S, Casalini A, Tassi G, Puntoni R, Mutti L, Procopio A. Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J. Pathol., 193, 468-475 (2001).
5. Harris AL. Hypoxia-A key regulator factor in tumour growth. Nat. Rev. Cancer, 2, 38-47 (2002).
6. Denko NC, Fontana LA, Hudson KM, Sutphin PD, Raychaudhuri S, Altman R, Giaccia AJ. Investigating hypoxic tumor physiology through gene expression patterns. Oncogene, 22, 5907-5914 (2003).
7. Klabatsa A, Sheaff MT, Steele JP, Evans MT, Rudd RM, Fennell DA. Expression and prognostic significance of hypoxia-inducible factor 1 alpha (HIF-1 alpha) in malignant pleural mesothelioma (MPM). Lung Cancer, 51, 53-59 (2006).
8. Semenza GL. Hypoxia-inducible factor 1 and the molecular physiology of oxygen homeostasis. J. Lab. Clin. Med., 131, 207-214 (1998).
9. Maxwell PH, Dachs GU, Gleadle JM, Nicholls LG, Harris AL, Stratford IJ, Hankinson O, Pugh CW, Ratcliffe PJ. Hypoxia-inducible factor 1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc. Natl. Acad. Sci. U.S.A., 94, 8104-8109 (1997).
10. Kashiwagi K, Harada K, Yano Y, Kumadaki I, Hagiwara K, Takebayashi J, Kido W, Virgona N, Yano T. A redox-silent analogue of tocotrienols inhibits hypoxic adaptation of lung cancer cells. Biochem. Biophys. Res. Commun., 365, 875-881 (2008).
11. Sato H, Hagiwara H, Ohde Y, Senba H, Virgona N, Yano T. Regulation of renal cell carcinoma cell proliferation, invasion and metastasis by connexin 32 gene. J. Membr. Biol., 216, 17-21 (2007).
12. Gray MJ, Zhang J, Ellis LM, Semenza GL, Evans DB, Watowich SS, Gallick GE. HIF-1 alpha, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Srcdependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas. Oncogene, 24, 3110-3120 (2005).
13. Weis S, Cui J, Barnes L, Cheresh D. Endothelial barrier disruption by VEGF-mediated Src activity potentiates tumor cell extravasation and metastasis. J. Cell Biol., 167, 223-229 (2004).
14. Sato A, Sekine M, Virgona N, Ota M, Yano T. Yes is a central mediator of cell growth in malignant mesothelioma cells. Oncol. Rep., 28, 1889-1893 (2012).
15. Shibata A, Nakagawa K, Sookwong P, Tsuduki T, Tomita S, Shirakawa H, Komai M, Miyazawa T. Tocotrienol inhibits secretion of angiogenic factors from human colorectal adenocarcinoma cells by suppressing hypoxia-inducible factor-1alpha. J. Nutr., 138, 2136-2142 (2008).
16. Bi S, Liu JR, Li Y, Wang Q, Liu HK, Yan YG, Chen BQ, Sun WG. Gamma-Tocotrienol modulates the paracrine secretion of VEGF induced by cobalt(II) chloride via ERK signaling pathway in gastric adenocarcinoma SGC-7901 cell line. Toxicology, 274, 27-33 (2010).
17. Ahluwalia AS, Tarnawski A. Critical role of hypoxia sensor-HIF-1α in VEGF gene activation. Implications for angiogenesis and tissue injury healing. Curr. Med. Chem., 19, 90-97 (2012).
18. Uchida T. Prolonged hypoxia differentially regulates hypoxiainducible factor (HIF)-1alpha and HIF-2alpha expression in lung epithelial cells: implication of natural antisense HIF-1alpha. J. Biol. Chem., 279, 14871-14878 (2004).
19. Wei W, Yu XD. Hypoxia-inducible factors: crosstalk between their protein stability and protein degradation. Cancer Lett., 257, 145-156 (2007).
20. Chatzizacharias NA, Kouraklis GP, Giaginis CT, Theocharis SE. Clinical significance of Src expression and activity in human neoplasia. Histol. Histopathol., 27, 677-692 (2012).
21. Yano T, Sato A, Sekine M, Virgona N, Ota M. Redox-inactive analogue of tocotrienol as a potential anti-cancer agent. Anticancer. Agents Med. Chem., 13, 496-501 (2013).
22. Kashiwagi K, Virgona N, Harada K, Kido W, Yano Y, Ando A, Hagiwara K, Yano T. A redox-silent analogue of tocotrienol acts as a potential cytotoxic agent against human mesothelioma cells. Life Sci., 84, 650-656 (2009).
23. Shibata A, Nakagawa K, Sookwong P, Tsuzuki T, Oikawa S, Miyazawa T. Tumor anti-angiogenic effect and mechanism of action of delta-tocotrienol. Biochem. Pharmacol., 76, 330-339 (2008).
24. Sia D, Alsinet C, Newell P, Villanueva A. VEGF signaling in cancer treatment. Curr. Pharm. Des. (2013), in press.
25. Shibata A, Nakagawa K, Sookwong P, Tsuduki T, Oikawa S, Miyazawa T. Delta-tocotrienol suppresses VEGF induced angiogenesis whereas alpha-tocopherol does not. J. Agric. Food Chem., 57, 8696-8704 (2009).